Media headlines about Medidata Solutions (NASDAQ:MDSO) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Medidata Solutions earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.8650905050337 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Dougherty & Co Upgrades Medidata Solutions, Inc. (MDSO) to “Buy” (americanbankingnews.com)
- $141.82 Million in Sales Expected for Medidata Solutions, Inc. (MDSO) This Quarter (americanbankingnews.com)
- ETFs with exposure to Medidata Solutions, Inc. : November 9, 2017 (finance.yahoo.com)
- Medidata Honors 2017 Architects of Hope Award Winners at Medidata NEXT Global (finance.yahoo.com)
- $0.31 Earnings Per Share Expected for Medidata Solutions, Inc. (MDSO) This Quarter (americanbankingnews.com)
MDSO has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of Medidata Solutions from a “hold” rating to a “sell” rating in a research report on Friday, July 21st. Wells Fargo & Company reduced their target price on shares of Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating for the company in a research note on Friday, October 27th. J P Morgan Chase & Co upped their target price on shares of Medidata Solutions to $87.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 18th. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $92.00 target price on shares of Medidata Solutions in a research note on Friday, October 27th. Finally, Citigroup Inc. reaffirmed a “buy” rating and issued a $95.00 target price (up from $94.00) on shares of Medidata Solutions in a research note on Monday, July 24th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $83.54.
Medidata Solutions (NASDAQ MDSO) traded down $0.37 during trading on Wednesday, hitting $66.58. 464,400 shares of the stock were exchanged, compared to its average volume of 548,450. Medidata Solutions has a one year low of $47.77 and a one year high of $85.92. The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.37 and a current ratio of 1.29. The firm has a market cap of $3,913.96, a P/E ratio of 80.66, a price-to-earnings-growth ratio of 4.03 and a beta of 1.78.
Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings data on Thursday, October 26th. The company reported $0.33 EPS for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.02. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The company had revenue of $140.08 million during the quarter, compared to the consensus estimate of $141.27 million. During the same period in the prior year, the business posted $0.28 EPS. The company’s quarterly revenue was up 16.7% on a year-over-year basis. analysts expect that Medidata Solutions will post 0.77 earnings per share for the current year.
In other news, Director Robert Taylor sold 5,000 shares of the stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $71.39, for a total transaction of $356,950.00. Following the completion of the transaction, the director now directly owns 49,372 shares in the company, valued at approximately $3,524,667.08. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Michael I. Otner sold 10,000 shares of the stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $70.88, for a total transaction of $708,800.00. Following the transaction, the executive vice president now owns 80,674 shares of the company’s stock, valued at $5,718,173.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 215,000 shares of company stock valued at $14,817,750. Company insiders own 5.80% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://ledgergazette.com/2017/11/15/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-medidata-solutions-mdso-stock-price.html.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.